-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ERpj8+PP7soIrU7c9ka3f0KjOCNHHPbJAELVRxuOBw0fOJbOW+WioR9g8yj7S2P7 t4V0GA+QEThDaST9IylZoA== 0001230295-06-000185.txt : 20060706 0001230295-06-000185.hdr.sgml : 20060706 20060706161211 ACCESSION NUMBER: 0001230295-06-000185 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060630 FILED AS OF DATE: 20060706 DATE AS OF CHANGE: 20060706 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KLEIN JOSEPH III CENTRAL INDEX KEY: 0001206369 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 06948193 BUSINESS ADDRESS: BUSINESS PHONE: 2037731450 MAIL ADDRESS: STREET 1: C/O GENAISSANCE PHARMACEUTICALS INC STREET 2: FIVE SCIENCE PARK CITY: NEW HAVEN STATE: CT ZIP: 06511 4/A 1 kle91.xml X0202 4/A 2006-06-30 2006-07-05 0 0000722104 SAVIENT PHARMACEUTICALS INC SVNT 0001206369 KLEIN JOSEPH III C/O SAVIENT PHARMACEUTICALS, INC ONE TOWER CENTER BLVD. EAST BRUNSWICK NJ 08816 1 0 0 0 Common Stock, $.01 par value per share 2006-06-30 4 A 0 306 5.2500 A 26306.0000 D Option to Purchase Common Stock, $.01 par value 5.2500 2006-06-30 4 A 0 2143 5.2500 A 2007-06-30 2016-06-30 Common Stock, $.01 par value per share 2143.0000 2143.0000 D These shares were granted pursuant to the Company's 2004 Incentive Plan, which provides for the grant to non-employee directors of that number of shares of Common Stock having an aggregate fair market value on the last business day of each quarter equal to $3,750.00, until he is no longer an Outside Director. On June 30, 2006, the fair market value of the Common Stock, based on the closing price, was $5.25. These options will become fully vested and immediately exercisable on 6/30/2007. Due to an administrative typo, the original timely filed Form 4 showed an incorrect amount in the 'Amount of Number of Shares' column. By: Beata A. Smith as Attorney-In-Fact for 2006-06-30 -----END PRIVACY-ENHANCED MESSAGE-----